Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 505-514

  Giannousis, Ioannis P ^a   Manolakopoulos, Spilios G ^a   Hadziyannis, Emilia ^a   Georgiou, Anastasia ^a   Papatheodoridis, George V ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENINE; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KERATIN-18; LAMIVUDINE; PHOSPHONIC ACIDS;

EID: 79959406699     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1775     Document Type: Article

References (24)

1. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8:167-178. (Pubitemid 351249242)
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
4. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54:1024-1033. (Pubitemid 40873921)
5. Kiyici M, Gurel S, Budak F, et al. Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol 2003; 15:1079-1084. (Pubitemid 37267222)
6. Janssen HL, Higuchi H, Abdulkarim A, Gores G. Hepatitis B virus enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003; 39:414-420. (Pubitemid 37070259)
7. Foo NC, Ahn BY, Ma X, Hyun W, Yen TS. Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein. Hepatology 2002; 36:1400-1407. (Pubitemid 35403531)
8. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40:1078-1087. (Pubitemid 39425563)
9. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44:27-33. (Pubitemid 44049136)
10. Gonzalez-Quintela A, Abdulkader I, Campos J, Fernandez-Hernandez L, Lojo S. Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 2009; 54:648-653.
11. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases - detection and therapeutic applications. Med Sci Monit 2005; 11:RA337-RA345.
12. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157:1415-1430.
13. Fischer U, Jänicke RU, Schuzle-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003; 10:76-100.
14. Van Eyken P, Desmet VJ. Cytokeratins and the liver. Liver 1993; 13:113-122. (Pubitemid 23228705)
15. Leers MP, Kölgen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187:567-572. (Pubitemid 29151999)
16. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80:230-239. (Pubitemid 32241930)
17. Grassi A, Susca M, Ferri S, et al. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol 2004; 121:211-219. (Pubitemid 38140125)
18. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008; 57:500-506. (Pubitemid 351442534)
19. Paraskevis D, Haida C, Tassopoulos N, et al. Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J Virol Methods 2002; 103:201-212 [Erratum in: J Virol Methods 2003; 110:115].
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
21. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134:1641-1654. (Pubitemid 351615416)
22. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long term lamivudine therapy. Gastroenterology 2003; 124:105-117. (Pubitemid 36055344)
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
24. Volkmann X, Cornberg M, Wedemeyer H, et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006; 43:1311-1316. (Pubitemid 43980110)